We may use cookies to improve your experience with our website and to provide you with more relevant content based on your interests. To learn more about what information we collect, how we use it, and how to manage cookies, review our Privacy Policy.

Background on Co-Promote Agreement Between Exact Sciences and Ironwood Pharmaceuticals

EXACT SCIENCES CORPORATION

  • Exact Sciences Corp (NASDAQ: EXAS) is headquartered in Madison, WI with a 140- person sales team that is expected to reach 200 by Q4 2015.
  • The company has a market cap of ~$2B and a cash balance of $282.8M as of December 31, 2014. The company posted $1.5M in revenue during Q4 2014, its first full quarter with Cologuard® on the market.

Cologuard® overview

  • In Q3 2014 the FDA approved Cologuard, Exact Sciences’ noninvasive, stool DNA colorectal cancer screening test.
  • Cologuard is the first noninvasive screening test for colorectal cancer screening in average risk patients that analyzes both stool DNA and blood biomarkers.
  • Cologuard, which is available through healthcare providers, offers people 50 and older at average risk for colorectal cancer an easy-to-use screening test they can do in the privacy of their own home.

Cologuard® sales team overview

  • 140 sales professionals increased from 80 sales professionals on March 1, 2015 who target GIs and PCPs.
  • Average >10 years of experience for each professional.

IRONWOOD PHARMACEUTICALS CORPORATION:

  • Ironwood Pharmaceuticals (NASDAQ: IRWD) is headquartered in Cambridge, MA.
  • The company is focused on its strategy to build a leading pharmaceutical company grounded in a strong base of GI leadership.
  • Ironwood and its U.S. partner Actavis continue to maximize LINZESS, which is on strong trajectory with continued growth in Rx demand.
  • The company is also advancing multiple product candidates targeting large unmet needs in millions of patients, representing multi-billion dollar product opportunities.
  • Ironwood has a ~$2.2B market cap and ~$248M in cash as of December 31, 2014.
  • Ironwood has prior experience with co-promote agreements, including:
  • US – Actavis (formerly Forest Laboratories) starting in Q4 2012 (Actavis co- promotes LINZESS)
  • US – AstraZeneca (IRWD previously co-promoted AZ’s Nexium)

LINZESS® overview

  • LINZESS was approved in the U.S. in August 2012 for the treatment of adults with IBS with constipation (IBS-C) or chronic idiopathic constipation (CIC). Ironwood and Actavis began commercializing LINZESS in the U.S. in December 2012. In FY 2014 LINZESS had $297M in net sales.
  • Ironwood and Actavis jointly develop and commercialize LINZESS in the U.S., sharing equally in any net profits or losses.

LINZESS sales team overview

  • ~160 sales representatives who are targeting more than 25,000 physicians, including both GIs and high prescribing PCPs.

Co-Promote Terms

  • Ironwood’s sales force will target ~25,000 physicians, including both GIs and PCPs.
  • Cologuard will be in the second position (P2) in the Ironwood sales bag (LINZESS remains P1).
  • Ironwood will be compensated from the net sales generated from the physicians on whom they call.
  • The companies will collaborate on medical education initiatives to support more in-depth understanding of Cologuard and the importance of colorectal cancer screening.
  • Exact Sciences will maintain responsibility for all other aspects of commercialization of Cologuard.
  • The non-exclusive co-promotion agreement covers an initial one-year term with the opportunity for extension.
  • The agreement is exclusive to the United States.

What this agreement means for Exact Sciences

  • More than doubles the sales team’s coverage for Cologuard, adding ~160 sales professionals from Ironwood.
  • Accelerates Exact Sciences’ already growing medical education program.
  • Immediately advances awareness of Cologuard among health care providers as Exact Sciences simultaneously expands its sales force to 200 professionals during 2015.

What this agreement means for Ironwood Pharmaceuticals

  • Ironwood believes that providing an additional innovative product like Cologuard will drive additional LINZESS revenues by increasing the effectiveness of its LINZESS selling effort, meeting a critical patient need and strengthening the value Ironwood brings to healthcare professionals
  • Ironwood’s promotional efforts for Cologuard are fully aligned with its existing Ironwood sales force call points, leverages its strong commercial capabilities and further establishes Ironwood as a leading GI company
  • It is also immediately accretive and essentially 100% efficient, with no additional unreimbursed costs required to promote Cologuard, and the Ironwood sales force will continue to have further capacity for additional proprietary products and co-promotes
Topics: Exact Sciences News

Subscribe To The Blog